PATENT CLAIM ANALYSIS

Application Number: 16118760
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-03
Patent Classification: ["546", "119000"]

Abstract:
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

Claim (Index 41):
The method of  claim 39  further comprising administering to the individual at least one additional therapeutic agent selected from the group consisting of an HBV polymerase inhibitor, immunomodulatory agents, pegylated interferon, viral entry inhibitor, viral maturation inhibitor, literature-described capsid assembly modulator, reverse transcriptase inhibitor, a cyclophilin/TNF inhibitor, a TLR-agonist, an HBV vaccine, and agents of distinct or unknown mechanism, and a combination thereof.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 96.0
- Lexical Diversity: 1.42308
- Patent Class: 546.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14984325', '15843598', '14984293', '15347468', '14984654']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8642503081711355
- 35 USC 102 Novelty (BERT): 0.6329833544875795
- Combined Prediction Score: 0.8411236128027799
- Mean Citation Score: 697.37725
- Max Citation Score: 724.7858
- Similarity Product: 548.3535121842384

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test